<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Microbiol Biotechnol</journal-id><journal-id journal-id-type="iso-abbrev">J Microbiol Biotechnol</journal-id><journal-title-group><journal-title>Journal of Microbiology and Biotechnology</journal-title></journal-title-group><issn pub-type="ppub">1017-7825</issn><issn pub-type="epub">1738-8872</issn><publisher><publisher-name>The Korean Society for Microbiology and Biotechnology</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40374533</article-id><article-id pub-id-type="pmc">PMC12099627</article-id>
<article-id pub-id-type="doi">10.4014/jmb.2502.02035</article-id><article-id pub-id-type="publisher-id">jmb-35-e2502035</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research article</subject><subj-group><subject>Food Microbiology and Biotechnology (FMB)</subject><subj-group><subject>Bioactive Compounds and Functional Foods</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>7,7-Bis(3-Indolyl)-<italic toggle="yes">p</italic>-Cresol, a Metabolite from Marine-Derived Bacterium <italic toggle="yes">Vibrio</italic> spp. DJA11, Suppresses the Proliferation and Motility of Prostate Cancer Cells</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Pulat</surname><given-names>Sultan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lee</surname><given-names>Eun-Young</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Grace</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Jung</surname><given-names>Yoon-Hee</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nam</surname><given-names>Sang-Jip</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kim</surname><given-names>Hangun</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor2" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff1"><label>1</label>College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, 255 Jungangno, Sunchon, Jeonnam 57922, <country>Republic of Korea</country></aff><aff id="aff2"><label>2</label>Department of Chemistry and Nanoscience, Ewha Womans University, Seoul 03760, <country>Republic of Korea</country></aff><aff id="aff3"><label>3</label>Graduate Program in Innovative Biomaterials Convergence, Ewha Womans University, Seoul 03760, <country>Republic of Korea</country></aff><aff id="aff4"><label>4</label>Department of Biomaterial Research, National Marine Biodiversity Institute of Korea, Seocheon 33662, <country>Republic of Korea</country></aff><author-notes><corresp id="cor1">
<label>*</label>Corresponding authors SJ Nam E-mail: <email xlink:href="sjnam@ewha.ac.kr">sjnam@ewha.ac.kr</email></corresp><corresp id="cor2">
H Kim E-mail: <email xlink:href="hangunkim@sunchon.ac.kr">hangunkim@sunchon.ac.kr</email>
</corresp><fn id="fn1" fn-type="equal"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>5</month><year>2025</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>35</volume><elocation-id>e2502035</elocation-id><history><date date-type="received"><day>21</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>19</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 by the authors. Licensee KMB</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is an open access article distributed under the terms and conditions of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution (CC BY) license</ext-link></license-p></license></permissions><abstract><p>Bacteria such as <italic toggle="yes">Vibrio</italic> spp. in the marine environment can produce secondary metabolites which have significant potential applications in pharmaceuticals. In a study to discover bioactive secondary metabolites from marine <italic toggle="yes">Vibrio</italic> spp., the strain DJA11 was encountered. HPLC/UV-guided isolation of the crude extract from this strain has led to the discovery of compound 1. Prostate cancer (PCa) is one of the biggest worldwide health issues because of its high diagnosis. CWR22Rv1 (22Rv1) is mutated in WT p53 and AR, C4-2 is derived from androgen-dependent human LNCaP and PC-3 is an androgen-independent cancer cell type. It was found that compound 1 exhibited no significant cytotoxicity at concentrations below 50 &#x003bc;M to human PCa cells, including 22Rv1, C4-2, and PC-3, like normal cell HEK293T. In addition, we presented that 1 inhibited the invasiveness and proliferation of 22Rv1, PC-3, and C4-2 cells by suppressing the activation of p-AKT, p-mTOR, p-STAT3, HSP90, and HSP70. Moreover, treatment with 1 decreased the mRNA expression level of ErbB4, PDK1, STAT3, HSP70, and HSP90 in some PCa cells. Therefore, compound 1 may have therapeutic potential in PCa due to its role in suppressing cancer proliferation and metastasis.</p></abstract><kwd-group><kwd>Marine natural product</kwd><kwd><italic toggle="yes">Vibrio</italic> spp.</kwd><kwd>prostate cancer</kwd><kwd>proliferation</kwd><kwd>motility</kwd><kwd>AKT/mTOR</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Marine environments are an untapped reservoir of diverse microorganisms, including bacteria, fungi, and archaea, which are known to produce unique bioactive compounds [<xref rid="ref1" ref-type="bibr">1</xref>, <xref rid="ref2" ref-type="bibr">2</xref>]. Among these, species of the genus <italic toggle="yes">Vibrio</italic> have attracted particular attention due to their remarkable adaptability to diverse and often extreme marine habitats, which promotes the synthesis of complex secondary metabolites [<xref rid="ref3" ref-type="bibr">3</xref>, <xref rid="ref4" ref-type="bibr">4</xref>] <italic toggle="yes">Vibrio</italic> spp. are Gram-negative, rod-shaped bacteria that inhabit a wide range of aquatic ecosystems, including freshwater systems, estuarine environments, and marine habitats [<xref rid="ref5" ref-type="bibr">5</xref>]. This ecological versatility facilitates their production of a diverse array of secondary metabolites. Beyond their ecological role as a vital component of the marine food web, <italic toggle="yes">Vibrio</italic> spp. is a valuable source of bioactive molecules with significant potential applications in pharmaceuticals, nutraceuticals, and various other industries.</p><p>The unique metabolic versatility of marine-derived <italic toggle="yes">Vibrio</italic> spp. is demonstrated by their capacity to produce structurally diverse compounds, including alkaloids [<xref rid="ref6" ref-type="bibr">6</xref>], polyketides [<xref rid="ref7" ref-type="bibr">7</xref>], nonribosomal peptides [<xref rid="ref8" ref-type="bibr">8</xref>], and others, many of which exhibit potent antibacterial [<xref rid="ref9" ref-type="bibr">9</xref>], antimicrobial [<xref rid="ref10" ref-type="bibr">10</xref>], antifungal, anticancer, and antioxidant activities [<xref rid="ref4" ref-type="bibr">4</xref>]. As a part of collaborative study to discover bioactive secondary metabolites from marine <italic toggle="yes">Vibrio</italic> spp., the strain DJA11 was encountered. HPLC/UV-guided isolation of the crude extract from this strain has led to the discovery of compound <bold>1</bold>.</p><p>HPLC-UV-guided fractionation of the crude extract from the DJA11 strain, isolated from <italic toggle="yes">Ulva australis</italic>, has led to the identification of 7,7-bis(3-indolyl)-<italic toggle="yes">p</italic>-cresol (<bold>1</bold>). The chemical structure was elucidated based on detailed spectroscopic data, analyses, including MS, UV, and NMR, and further validated through a comparative assessment with the previously reported structure.</p><p>Prostate cancer (PCa) is one of the most commonly diagnosed cancers worldwide, it is the third most common cancer type in men [<xref rid="ref11" ref-type="bibr">11</xref>, <xref rid="ref12" ref-type="bibr">12</xref>]. The number of PCa cases increases each year in the world, World Health Organization (WHO) statistics show PCa cases rose from 1.1 million in 2012 to over 1.4 million in 2020 [<xref rid="ref13" ref-type="bibr">13</xref>].</p><p>In this research, three different prostatic cancer cells were selected, the normal cell was chosen for comparison of the effect of PCa cells and normal cells; CWR22Rv1 (22Rv1), C4-2, PC-3, and HEK293T (human embryonic kidney) cells. 22Rv1 is an androgen-independent human prostate carcinoma cell, which has a mutation in WT p53 and AR (T877A) [<xref rid="ref14" ref-type="bibr">14</xref>]. C4-2 prostatic cancer cells are derived from androgen-dependent human LNCaP [<xref rid="ref15" ref-type="bibr">15</xref>]. PC-3 cells cannot produce prostate-specific antigen (PSA) and are androgen-independent which distinguishes PC-3 cells from 22Rv1 and C4-2 [<xref rid="ref16" ref-type="bibr">16</xref>]. The three different PCa cells, classified as AR-dependent or AR-independent, allowed us to assess the anti-cancer effect of compound <bold>1</bold> across various PCa phenotypes and determine whether <bold>1</bold> suppresses the PCa metastasis and proliferation via AR or other signalings.</p><p>PCa is associated with over-activating AKT-mTOR signal pathways like many human cancers. mTOR has two distinct complexes which are mTORC1 and mTORC2. mTORC2 serves as an upstream kinase in the AKT-mTOR signal pathway [<xref rid="ref17" ref-type="bibr">17</xref>, <xref rid="ref18" ref-type="bibr">18</xref>]. Heat shock proteins 70 (HSP70) can control protein homeostasis, and signal transduction. Overexpression of HSP70 has negative outcomes like promoting cell viability, cancer metastasis, and inhibiting chemotherapy efficiency [<xref rid="ref19" ref-type="bibr">19</xref>]. PI3K/AKT/GSK3&#x003b2; signal pathway induced overexpression of HSF1 which has a crucial role in HSP70 protein synthesis [<xref rid="ref20" ref-type="bibr">20</xref>]. Everolimus is used as an mTOR inhibitor in the suppression of cancer development, however, its clinical application is limited because of side effects. Everolimus suppresses PI3K/AKT/mTOR by blocking the mTOR which promotes cancer cell metastasis and proliferation. Although the anticancer effect of mTOR inhibitor, everolimus, was reported, a previous study demonstrated that it promotes treatment-related death in cancer patients. Therefore, investigating a new compound that inhibits mTOR and AKT activity is crucial for cancer treatment [<xref rid="ref21" ref-type="bibr">21</xref>].</p><p>As a transcription factor, STAT3 is translocated to the nucleus and binds to the specific target gene on DNA therefore, it can control gene transcription. HSP90 supports the STAT3 activation by enhancing the phosphorylation, and translocation of STAT3 to bind the target gene [<xref rid="ref22" ref-type="bibr">22</xref>].</p><p>The androgen receptor (AR) is a kind of ligand-dependent nuclear transcription factor that can bind to testosterone or dihydrotestosterone (DHT), over-activation of AR causes the proliferation and survival of PCa cells [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>]. Heat shock proteins 90 (HSP90) and HSP70 interact with AR thereby enhancing the stability of the AR [<xref rid="ref25" ref-type="bibr">25</xref>]. One of the most popular AR inhibitors is enzalutamide, which prevents AR from interacting with DNA. However, its clinical application is limited because long-term use increases the risk of cardiovascular disease due to side effects. Thereby, the investigation of the alternative compounds that suppress AR in cancer treatment is important for effective cancer treatments [<xref rid="ref26" ref-type="bibr">26</xref>].</p><p>Previous studies have demonstrated that <bold>1</bold> has an anticancer effect on the metastatic potential of hormone-dependent and hormone-independent breast cancer and an anti-proliferative effect on lung cancer [<xref rid="ref27" ref-type="bibr">27</xref>, <xref rid="ref28" ref-type="bibr">28</xref>]. However, the anticancer effect of <bold>1</bold> in PCa cells has not been thoroughly investigated. In this study, we aimed to investigate the effects of <bold>1</bold> on the proliferation and metastasis of PCa cells; CWR22Rv1 (22Rv1), C4-2, and PC-3 through affect key signaling, including p-AKT, p-mTOR, p-STAT3, HSP90 HSP70 ErbB4, and PDK1.</p><p>The effect of <bold>1</bold> on cell viability was assessed by MTT assay, while its on PCa cell invasion ability was evaluated by trans well invasion. The effect of <bold>1</bold> on proliferation was tested by clonogenic assay. These phenotypic assay results were confirmed with the protein level by western blot and mRNA expression levels by quantitative real-time PCR.</p></sec><sec sec-type="other"><title>Experimental Section</title><sec><title>General Experimental Procedures</title><p>NMR spectra were acquired using an Agilent 400-MR DD2 spectrometer (Agilent Technologies, USA) at 400 MHz and 100 MHz for <sup>1</sup>H and <sup>13</sup>C NMR, respectively, containing Me<sub>4</sub>Si as internal standard and using solvent DMSO-<italic toggle="yes">d<sub>6</sub></italic> (Cambridge Isotope Laboratories (CIL), Inc., USA) equipped at Ewha Drug Development Research Core Center. Low-resolution LC-MS measurements were performed using the Agilent Technology 1260 quadrupole (Agilent Technologies) and Waters Alliance Micromass ZQ LC-MS system (Waters Corp., USA) using reversed-phase column (Phenomenex Luna C18 (2) 100 &#x000c5;, 100 mm &#x000d7; 4.6 mm, 5 mm) (Phenomenex, USA) at a flow rate 1.0 ml/min at the National Research Facilities and Equipment Center (NanoBioEnergy Materials Center) at Ewha Womans University.</p></sec><sec><title>Isolation and Identification of the Strain</title><p>We isolated the DJA11 strain from <italic toggle="yes">Ulva australis</italic> collected in Dangjin, Chungcheongnam-do, South Korea (37&#x000b0;1' 3.8'' N 126&#x000b0; 27' 42.3'' E). In detail, the collected <italic toggle="yes">Ulva australis</italic> was first throughly washed with sterilized seawater to remove any debris and contaminations. It was then finely chopped using sterilized scissors and ground into a paste with a sterilized mortar and pestle inside a clean bench to ensure aseptic conditions. The resulting homogenate was suspended in sterilized seawater and diluted to a 1:20 ratio. This diluted suspension was spread onto Marine Broth 2216 (Merck Group, Germany) agar plates, which were incubated to promote microbial growth. Through repeated streaking and subculturing, the pure strain DJA11 was successfully isolated.</p><p>For species identification of the DJA11 strain, 1 ml of the culture grown in marine broth liquid medium at 27&#x000b0;C for 4 days was harvested. Genomic DNA was then extracted using a Tissue Genomic DNA Kit (Cosmogenetech Co. Ltd., Republic of Korea), following the manufacturer&#x02019;s protocol. For 16S rRNA gene amplification to identify the DJA11 strain, PCR was performed using the primers 27F and 1492R. The PCR product was purified using a PCR purification Kit (Cosmogenetech Co. Ltd.) and sequenced using a capillary electrophoresis system (Applied Biosystems 3730XL). The resulting 16S rRNA gene sequence obtained from the DJA11 strain was compared to previously reported sequences in the GenBank/EMBL/DDBJ database using BLAST search. As a result, the 16S rRNA gene sequence of the DJA11 strain showed 99.9% similarity to that of <italic toggle="yes">Vibrio kanaloae</italic> LMG 20539, indicating that the DJA11 strain belongs to the <italic toggle="yes">Vibrio</italic> genus. The DJA11 strain was deposited in the Korean Collection for Type Culture (KCTC) on August 20, 2024, and was assigned the accession number KCTC 16007BP.</p></sec><sec><title>Cultivation and Extraction</title><p>The strain DJA11 was cultured in 80 &#x000d7; 2.5 L Ultra Yield flasks each containing 1 L of medium (37.4 g/l marine broth 2216 (BD Difco<sup>TM</sup>, USA) dissolved in distilled H<sub>2</sub>O) at 30&#x000b0;C with constant shaking at 130 rpm. After 6 days, the broth was extracted with EtOAc (80 L overall), and the EtOAc-soluble fraction was dried <italic toggle="yes">in vacuo</italic> to yield 1.30 g of organic extract.</p></sec><sec><title>Isolation of the Compound 1</title><p>The organic extract (1.30 g) was fractionated by C18 resin eluted with 100 ml H<sub>2</sub>O/CH<sub>3</sub>OH (80/20, 60/40, 50/ 50, 40/60, 30/70, 20/80, and 0/100) to obtain seven fractions (F1&#x02013;F7). Fraction 5 (F5) was further purified by reversed-phase HPLC (Phenomenex Luna C-18 (2), 250 &#x000d7; 100 mm, 2.0 ml/min, 5 mm, 100 &#x000c5;, UV = 210 nm) under an isocratic condition with 48% aqueous CH<sub>3</sub>CN (0.01% trifluoroacetic acid in H<sub>2</sub>O) to yield 7,7-bis(3-indolyl)-<italic toggle="yes">p</italic>-cresol (<bold>1</bold>, 3.4 mg, <italic toggle="yes">t</italic><sub>R</sub> = 45.5 min).</p><p><italic toggle="yes">7,7-Bis(3-indolyl)</italic>-<italic toggle="yes">p</italic>-<italic toggle="yes">cresol</italic>
<italic toggle="yes">(<bold>1</bold>)</italic>: yellow solid; <sup>1</sup>H NMR (400 MHz, DMSO-<italic toggle="yes">d<sub>6</sub></italic>): &#x003b4;<sub>H</sub> 10.75 (s, NH), 9.12 (s, OH), 7.32 (2H, d, <italic toggle="yes">J</italic> = 8.0 Hz, H-7', 7''), 7.25 (2H, d, <italic toggle="yes">J</italic> = 8.0 Hz, H-4', 4''), 7.13 (2H, d, <italic toggle="yes">J</italic> = 8.5 Hz, H-3, 5), 7.01 (2H, t, <italic toggle="yes">J</italic> = 8.6 Hz, H-6', 6''), 6.84 (2H, t, <italic toggle="yes">J</italic> = 8.6 Hz, H-5', 5''), 6.77 (2H, d, <italic toggle="yes">J</italic> = 2.0 Hz, H-2', 2''), 6.65 (2H, d, <italic toggle="yes">J</italic> = 8.5 Hz, H-2, 6) , 5.69 (<sup>1</sup>H, s, H-7); <sup>13</sup>C NMR (100 MHz, DMSO-<italic toggle="yes">d<sub>6</sub></italic>): &#x003b4;c 155.2 (C-1), 136.6 (C-7a', 7a''), 135.2 (C-4), 129.1 (C-3, 5), 126.6 (C-3a', 3a''), 123.3 (C-2', 2''), 120.7 (C-6', 6''), 119.2 (C-4', 4''), 118.6 (C-3', 3''), 118.0 (C-5', 5''), 114.7 (C-2, 6), 111.4 (C-7', 7''), 38.8 (C-7); LR-ESI-MS (positive) <italic toggle="yes">m/z</italic>: 338.2 [M + H]<sup>+</sup>.</p></sec><sec><title>Cell Culture</title><p>PCa cell lines 22Rv1, C4-2, PC-3, and HEK293T were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium or DMEM (Dulbecco's Modified Eagle Medium (Gen Depot, USA), supplemented with 10% FBS and 1%penicillin-streptomycin solution in a humid environment with 5% CO<sub>2</sub> [<xref rid="ref29" ref-type="bibr">29</xref>].</p></sec><sec><title>Methyl Thiazolyl Tetrazolium (MTT) Assay</title><p>PCa cell lines 22Rv1, C4-2, PC-3, and HEK293T were seeded on 96-well plates for grown overnight, and then treated with DMSO (Sigma-Aldrich, USA) or 10, 25, 50, and 100 &#x003bc;M of compound <bold>1</bold> for 48 h. The cells were lysed with 150 &#x003bc;l of DMSO after 4 h of incubation with MTT in 5% CO<sub>2</sub> at 37&#x000b0;C. The absorbance was measured at 540 nm using a microplate reader and analyzed with Gen 5 (2.03.1; BioTek, USA) [<xref rid="ref30" ref-type="bibr">30</xref>].</p></sec><sec><title>Invasion Assay</title><p>The 22Rv1, PC-3 (3 &#x000d7; 10<sup>5</sup>), and C4-2 (2.5 &#x000d7; 10<sup>5</sup>) cells were seeded in a culture medium containing 0.2% bovine serum albumin (BSA) and incubated with 5 and 10 &#x003bc;M of compound <bold>1</bold> or DMSO control for 24 h in polycarbonate membranes with 8 &#x003bc;m pores coated with 1% gelatin trans well chambers (Corning, USA). The lower chamber was filled with 600 &#x003bc;l RPMI containing 0.2% BSA and 6 &#x003bc;g/ml fibronectin (EMD Millipore Corp., USA) as a chemoattractant for 24 h incubation. Diff-Quik kit (Sysmex, Japan) was used for fixed and staining of invading cells. The number of cells was quantified using a Nikon Eclipse 400 fluorescence microscope (Nikon Instech, Co. Ltd., Japan) and i-Solution FL Auto Software (IMT i-Solution Inc., Canada; five fields/chamber) [<xref rid="ref31" ref-type="bibr">31</xref>].</p></sec><sec><title>Clonogenic Assay</title><p>22Rv1, PC-3, and C4-2 were seeded at a density of 0.5&#x02013;1&#x000d7;10<sup>3</sup> cells/well in RPMI medium and incubated to encourage attachment and then treated with DMSO, 5 &#x003bc;M, and 10 &#x003bc;M of <bold>1</bold>. Cells were stained with 0.01% crystal violet after seeding at 14 days, colony areas were measured by the IMT iSolutionFL software [<xref rid="ref32" ref-type="bibr">32</xref>].</p></sec><sec><title>Quantitative Real-Time PCR</title><p>Briefly, the total RNA of 22Rv1, PC-3, and C4-2 cells were isolated by using RNAiso Plus (Takara, Japan). Moloney murine leukemia virus reverse transcriptase (Invitrogen, USA) was used to convert RNA to cDNA, and relative gene expression was analyzed by the dye SYBR Green (Enzynomics, Republic of Korea). Further, the qRT-PCR reaction and analysis were performed using CFX (Bio-Rad, USA) [<xref rid="ref33" ref-type="bibr">33</xref>]. The primers used for real-time PCR were as follows: GAPDH (forward) 5'-ATCACCATCTTCCAGGAGCGA-3'; and Reverse 5&#x02019;-AGTTGTCATGGA TGACCTTGGC-3'; HSP70 (forward) 5'-TTGCGCAAGGCTCGGTACTG-3' and TTTTCTGCTGGTGTCTGCTG; HSP90 (forward) 5'- TTCTGCTTATTTGGTTGC-3' and 5'-AACTTTTGTTCCACGACC-3'; PDK1 (forward) 5'-TTACGGATTGCCCATATCACG-3' and 5'-CCCGGTCACTCATCTTCACAGT-3', ERBB4 (forward) 5'-ATGAAGCCGGCGACAGGACT-3' and5'-TTGCGCAAGGCTCGGTACTG-3'. GAPDH primer was used as a housekeeping gene for normalization.</p></sec><sec><title>Molecular Docking</title><p>The PDB structures of AKT1 (2XJX), mTOR (4JT6), and AR (2Q7I) were obtained from the RCSB PDB database, while the chemical structures of 1 (2940609) and testosterone (13475125) were extracted from the PubChem database for the docking analysis. Water molecules and the crystal ligand were removed from the protein-ligand complex before importing it into AutoDockTools (1.5.7) for docking. Two-dimensional (2D) and three-dimensional (3D) diagrams of intermolecular interactions were analyzed using Discovery Studio software.</p></sec><sec><title>Western Blots</title><p>22Rv1, PC-3, and C4-2 cells were treated with 5 or 10 &#x003bc;M of <bold>1</bold> for 24 h. 25 &#x003bc;g of lysed protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Multigauge 3.029 was used to measure bands for each sample and the results were normalized to that of &#x003b1;-tubulin or glyceraldehyde 3-phosphate dehydrogenase (GAPDH). &#x003b1;-tubulin and GAPDH were used as a loading control. Values were expressed as densitometric units, corresponding to the signal intensity [<xref rid="ref34" ref-type="bibr">34</xref>].</p></sec></sec><sec sec-type="results|discussion"><title>Results and Discussion</title><sec><title>Identification of Compound 1</title><p>Compound <bold>1</bold> was isolated as yellow solid, and LR-ESI-MS revealed an ionic peak at <italic toggle="yes">m/z</italic> 338.2 [M+H]<sup>+</sup>. The <sup>1</sup>H NMR spectrum of <bold>1</bold> showed two exchangeable protons at 1-OH (&#x003b4;<sub>H</sub> 9.12, s), and NH (&#x003b4;<sub>H</sub> 10.75, s), three methine proton at H-7 (&#x003b4;<sub>H</sub> 5.69, s, <sup>1</sup>H), H-2' and H-2'' (&#x003b4;<sub>H</sub> 6.77, d, <italic toggle="yes">J</italic> = 2.0 Hz, 2H), and fourteen aromatic protons at H-2 and H-6 (&#x003b4;<sub>H</sub> 6.65, d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), H-3 and H-5 (&#x003b4;<sub>H</sub> 7.13, d, <italic toggle="yes">J</italic> = 8.5 Hz, 2H), H-5' and H-5'' (&#x003b4;<sub>H</sub> 6.84, t, <italic toggle="yes">J</italic> = 8.6 Hz, 2H), H-6' and H-6'' (&#x003b4;<sub>H</sub> 7.01, t, <italic toggle="yes">J</italic> = 8.6 Hz, 2H), H-4' and H-4'' (&#x003b4;<sub>H</sub> 7.25, d, <italic toggle="yes">J</italic> = 8.0 Hz, 2H), and H-7' and H-7'' (&#x003b4;<sub>H</sub> 7.32, d, <italic toggle="yes">J</italic> = 8.0 Hz, 2H) (<xref rid="S1" ref-type="supplementary-material">Fig. S1</xref>). The <sup>13</sup>C NMR spectrum of <bold>1</bold> displayed eighteen carbons at C-1 (&#x003b4;c 155.2), C-2 and 6 (&#x003b4;c 114.7), C-3 and C-5 (&#x003b4;c 129.1), C-4 (&#x003b4;c 135.2), C-4' and 4'' (&#x003b4;c 119.2), C-5' and 5'' (&#x003b4;c 118.0), C-6' and 6'' (&#x003b4;c 120.7), C-7' and 7'' (&#x003b4;c 111.4), C-3a' and 3a'' (&#x003b4;c 126.6), C-7a' and 7a'' (&#x003b4;c 136.6), two indole moeity carbons at C-2' and C-2'' (&#x003b4;c 123.3), and C-3' and C-3'' (&#x003b4;c 118.6), and one methine carbon at C-7 (&#x003b4;c 38.8) (<xref rid="S1" ref-type="supplementary-material">Fig. S2</xref>). Based on the comparison of the <sup>1</sup>H NMR and <sup>13</sup>C NMR data of <bold>1</bold> with those reported in the literature, compound <bold>1</bold> was identified as 7,7-bis(3-indolyl)-<italic toggle="yes">p</italic>-cresol (<xref rid="F1" ref-type="fig">Fig. 1</xref>).</p></sec><sec><title>Effect of 1 on the Cell Viability of Prostate Cancer (PCa) Cell Lines</title><p>MTT assay was conducted to measure the effect <bold>1</bold> on PCa and HEK293T cell viability. 22Rv1, PC-3, C4-2, and HEK293T were seeded on a 96-well plate for grown overnight, and then treated with 10, 25, 50, and 100 &#x003bc;M of <bold>1</bold> for 48 h. For comparison of the effect of 1, three different PCa cells were selected in the study, as well as a human embryonic kidney as a control. Treatment with 10 and 25 &#x003bc;M of compound <bold>1</bold> did not inhibit the cell viability of PCa and HEK293T while 50 and 100 &#x003bc;M of compound <bold>1</bold> significantly inhibited the cell viability (<xref rid="F2" ref-type="fig">Fig. 2A</xref>). The IC<sub>50</sub> of <bold>1</bold> was 44.3 &#x003bc;M in 22Rv1, 60.7 &#x003bc;M in PC-3, 48 &#x003bc;M in C4-2, and 46.2 &#x003bc;M in HEK293T (<xref rid="F2" ref-type="fig">Fig. 2B</xref>). Thus, these observations demonstrate that a high concentration of compound <bold>1</bold> has a strong bioactivity for reducing PCa and normal cell viability. A nontoxic concentration of <bold>1</bold> (5 and 10 &#x003bc;M) was used to show the effect of <bold>1</bold> on PCa cell proliferation and metastasis for further analysis.</p></sec><sec><title>The Effects of 1 on the Motility and Proliferation of Prostate Cancer (PCa) Cell Lines</title><p>The PCa cells have longer life spans and higher proliferation capacity than normal cells therefore, suppressing proliferation is a promising strategy to reduce cancer mortality [<xref rid="ref35" ref-type="bibr">35</xref>]. Hence, a clonogenic assay was conducted to show whether treatment with 5 and 10 &#x003bc;M of <bold>1</bold> affects the proliferation of 22Rv1, PC-3, and C4-2 cells. As shown in <xref rid="F3" ref-type="fig">Fig. 3A</xref>, <bold>1</bold> significantly reduced the number of colonies by ~80%, ~30%, and ~35% at 10 &#x003bc;M on 22Rv1, PC-3, and C4-2, indicating that cell proliferation was inhibited. Taken together, these results indicated that 10 &#x003bc;M of <bold>1</bold> inhibited cell proliferation in 22Rv1, C4-2, and PC-3 cells.</p><p>Metastasis is the spreading of cancer cells to the secondary space of the body from where it started which is one of the main reasons for mortality in PCa patients [<xref rid="ref36" ref-type="bibr">36</xref>]. To elucidate whether 5 and 10 &#x003bc;M of <bold>1</bold> affect 22Rv1, PC-3, and C4-2 cell motility, an invasion assay was conducted. Treatment with 5 &#x003bc;M of <bold>1</bold> did not decrease the invaded ability of 22Rv1, C4-2, and PC-3 while 10 &#x003bc;M of <bold>1</bold> significantly inhibited the invaded ability of all three (<xref rid="F3" ref-type="fig">Fig. 3C</xref> and <xref rid="F3" ref-type="fig">3D</xref>). We show that a nontoxic concentration of <bold>1</bold> (10 &#x003bc;M) suppressed the invasion ability of PCa cells.</p></sec><sec><title>The Effects of 1 on the Protein Level of p-AKT, p-mTOR, p-STAT3, HSP90, and HSP70 in Prostate Cancer (PCa)</title><p><italic toggle="yes">In silico</italic>, the intracellular target for <bold>1</bold> was identified by Swiss Target Prediction. <bold>1</bold>&#x02019;s smile code was used for the target prediction species, which detected 100 different targets. Next, docking scores were shown based on the Swiss Target web server offers. As in <xref rid="F4" ref-type="fig">Fig. 4</xref>, <bold>1</bold> docking scores for mTOR, and HSP90, range from -7.4 to -8.1 kcal/mol through a conventional hydrogen bond, carbon-hydrogen bond, unfavorable donor-donor, pi-cation, pi-donor hydrogen, pi-sigma, pi-pi stacked, and pi-alkyl interactions.</p><p>Heat shock proteins are involved in mTOR signaling by affecting the proper protein folding [<xref rid="ref37" ref-type="bibr">37</xref>, <xref rid="ref38" ref-type="bibr">38</xref>]. STAT3 plays an important role in cancer proliferation and metastasis as a transcription factor, and STAT3 is one of the downstream targets of the AKT/mTOR pathway [<xref rid="ref39" ref-type="bibr">39</xref>, <xref rid="ref40" ref-type="bibr">40</xref>]. To determine whether the inhibition of motility in PCa cells in the presence of nontoxic concentrations of <bold>1</bold> involves AKT, mTOR, STAT3, HSP90, and HSP70, the protein level of these proteins was determined by western blot.</p><p>Compound <bold>1</bold> at 10 &#x003bc;M significantly decreased the protein level of p-AKT, p-mTOR, and p-STAT3 in three PCa cells. In addition, <bold>1</bold> also reduced the protein level of HSP90 and HSP70 (<xref rid="F4" ref-type="fig">Fig. 4B</xref> and <xref rid="F4" ref-type="fig">4C</xref>). These results show that <bold>1</bold> inhibited the invasiveness and proliferation of 22Rv1, PC-3, and C4-2 cells by suppressing the activation of p-AKT, p-mTOR, p-STAT3, HSP90, and HSP70, suggesting that <bold>1</bold> has therapeutic potential in PCa.</p></sec><sec><title>The Effect of 1 on mRNA Expression of ErbB4, PDK1, STAT3, HSP70, and HSP90 in Prostate Cancer (PCa)</title><p>ErbB4 is involved in the development of cancer by different signal pathways and mechanisms which include modifying the PI3K/AKT/mTOR pathways by promoting gene transcription by STAT3 [<xref rid="ref41" ref-type="bibr">41</xref>]. Phosphorylation of AKT is increased by different kinase types like PDK1 and mTORC2, and overexpression of AKT promotes cancer cell viability, proliferation, and tumor growth. In addition, PDK1 has a significant role in activating downstream targets such as AKT in PCa [<xref rid="ref42" ref-type="bibr">42</xref>]. This information suggests that ErbB4 and PDK1 can be therapeutic targets and may modulate sensitivity to cancer therapies. Treatment with 10 &#x003bc;M of <bold>1</bold> significantly inhibited the mRNA expression level of ErbB4, STAT3, and HSP70 while 10 &#x003bc;M of <bold>1</bold> did not change the mRNA expression level of PDK1, HSP90 in C4-2. In addition, we show that 10 &#x003bc;M of <bold>1</bold> decreased the mRNA expression level of PDK1, STAT3, and HSP70 whereas <bold>1</bold> did not affect the mRNA expression level of ErbB4 and HSP90 in PC-3 (<xref rid="F5" ref-type="fig">Fig. 5</xref>). Taken together, these results indicated that compound <bold>1</bold> inhibits different oncogenes expression levels across three types of PCa cells through various suppressed mechanisms.</p></sec><sec><title>The Effects of 1 on AR in Prostate Cancer (PCa)</title><p>AR is a steroid hormone receptor that binds testosterone and DHT, thereby promoting PCa progression [<xref rid="ref43" ref-type="bibr">43</xref>]. In silico, the intracellular target for <bold>1</bold> was identified by Swiss Target Prediction, docking scores were shown based on the Swiss Target web server offers. As in <xref rid="F6" ref-type="fig">Fig. 6</xref>, <bold>1</bold> docking scores for AR for <bold>1</bold> and testosterone are -7.4 and -7.5 kcal/mol through a conventional hydrogen bond, unfavorable donor-donor, Pi-cation, Pi-donor hydrogen, Pi-anion, and Pi-alkyl interactions. To elucidate whether 5 and 10 &#x003bc;M of <bold>1</bold> affect the AR on 22Rv1, and C4-2 cells, the mRNA expression level of AR was checked. Treatment with <bold>1</bold> decreased the mRNA expression level of AR in C4-2 cells while <bold>1</bold> did not affect this gene expression in 22Rv1 cells.</p></sec><sec><title>Target of Compound 1 and Prostate Cancer (PCa)</title><p>The Venny diagram shows genes associated with PCa, identifying 100 as potential targets of <bold>1</bold> (<xref rid="F7" ref-type="fig">Fig. 7A</xref>). Overlap between PCa&#x02019;s and potential targets of <bold>1</bold> in the intersection includes 84 genes, mTOR, HSP90AA1, AR, and PDK1 placed in this area. We indicated that the protein-to-protein network analysis of <bold>1</bold> (<xref rid="F7" ref-type="fig">Fig. 7B</xref>). Gene ontology analysis is shown in <xref rid="F7" ref-type="fig">Fig. 7C</xref> based on AKT, mTOR, STAT3 HSP90, HSP70, ErbB4, and PDK1. The signal pathways in which we show the protein or mRNA levels, are in the first 20-fold enrichment level. These signal pathways are the ErbB signaling pathway, PD-1 checkpoint pathway, JAK-STAT signaling pathway, PI3K-AKT signaling pathway, and pathways in cancer. ErbB signaling pathway regulates cancer cell proliferation with conjugation of AKT [<xref rid="ref44" ref-type="bibr">44</xref>]. The JAK-STAT signaling pathway is important in cancer progression high activation of this signal path promotes cell proliferation, and metastasis [<xref rid="ref45" ref-type="bibr">45</xref>]. We show that <bold>1</bold> significantly inhibited the protein level of p-AKT, p-mTOR, p-STAT3 HSP90, HSP70 and mRNA expression level of ErbB4, PDK1, STAT3, HSP70, and HSP90. These are components of the ErbB, JAK-STAT, and PI3K/AKT signaling pathway.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Compound 1 exhibits diverse biological activities, including antimicrobial effects [<xref rid="ref46" ref-type="bibr">46</xref>], and the ability to act as an antagonist of the orphan nuclear receptor Nur77 (NR4A1, TR3) [<xref rid="ref47" ref-type="bibr">47</xref>]. It induces reactive oxygen species (ROS) production and ER stress in pancreatic cancer cells [<xref rid="ref48" ref-type="bibr">48</xref>]. Moreover, it mimics Nur77 knockdown effects in non-small-cell lung cancer cells (A549, H460), resulting in the inhibition of proliferation, induction of apoptosis, and suppression of mTORC1 signaling [<xref rid="ref27" ref-type="bibr">27</xref>, <xref rid="ref48" ref-type="bibr">48</xref>]. Additionally, it downregulates &#x003b2;1- and &#x003b2;3-integrin expression, impairing breast cancer cell migration [<xref rid="ref28" ref-type="bibr">28</xref>], and decreases histone methyltransferase G9A (EHMT2) expression in alveolar rhabdomyosarcoma cells, underscoring its broad therapeutic potential [<xref rid="ref49" ref-type="bibr">49</xref>]. However, the biological activity of <bold>1</bold> in PCa cells has not been explored. We aim to investigate the anticancer effect of <bold>1</bold> in PCa, focusing on its ability to suppress cancer proliferation and metastasis which has a promising strategy to reduce PCa mortality.</p><p>Uncontrolled growth by high stimulation of some signal pathways is the reason for PCa in the gland which is placed in the reproductive system. PCa patients often do not have clear symptoms in the cancer early stage but in later stages, symptoms can be seen [<xref rid="ref50" ref-type="bibr">50</xref>]. The risk of developing PCa is associated with these factors; older age, race, family history, and obesity [<xref rid="ref51" ref-type="bibr">51</xref>]. Like other kinds of cancer PCa is caused by mutations in DNA that cause cells to have a longer life span and divide faster compared to normal cells. With the high proliferation capacity, these cells start to accumulate in their primary place and then according to their capacity, these cells can migrate to their secondary place by blood vessels. All these processes occur through signal pathways that are overstimulated.</p><p>In this study, we show that a high concentration of compound <bold>1</bold> has a strong suppressing effect on 22Rv1, C4-2, and PC-3 cell viability. PCa cells have a longer lifespan and a higher proliferation capacity than normal cells, so suppressing proliferation is a promising strategy to reduce cancer mortality. A nontoxic concentration of <bold>1</bold> inhibited cell proliferation and metastasis in PCa cells. Therefore, these results demonstrated that treatment with <bold>1</bold> showed an anti-cancer effect and a safer treatment without its non-toxic concentrations in PCa cells. In the other analyses focused on elucidating the underlying mechanisms by which compound <bold>1</bold> reduces cell proliferation and metastasis.</p><p>AKT can be activated by PDK1 and mTOR, and over-activation of AKT can cause proliferation and survival of cancer cells [<xref rid="ref42" ref-type="bibr">42</xref>]. We show treatment with <bold>1</bold> decreased significantly the protein level of p-AKT, and p-mTOR in three PCa cells.</p><p>Previous studies have shown that STAT3 is also an oncogenic protein that promotes primary prostate tumors and metastatic lesions in PCa [<xref rid="ref52" ref-type="bibr">52</xref>]. In this study, we indicate that treatment with <bold>1</bold> suppressed the protein level and mRNA expression level of STAT3 in three cancer cells.</p><p>PCa progression is mediated by HSP70 and HSP90, which are molecular chaperones, through increasing proliferation and metastasis capacity [<xref rid="ref53" ref-type="bibr">53</xref>]. The protein levels of HSP70 and HSP90 were decreased in three cells treatment with <bold>1</bold>. Moreover, the mRNA expression level of HSP90 was suppressed in PC-3 and 22Rv1. In addition, the mRNA expression level of HSP70 was suppressed treatment with <bold>1</bold> in C4-2. This study shows that compound <bold>1</bold> inhibits the expression levels of various oncogenes in three types of PCa cells through a variety of suppressed mechanisms.</p><p>AR has an important role in cell growth, and cell survival in normal PCa; however, mutations in the AR can contribute to PCa cell progression and therapy resistance. Current PCa treatment approaches inhibit proliferation and metastasis by suppressing AR [<xref rid="ref54" ref-type="bibr">54</xref>]. 22Rv1 is mutated in AR, C4-2 is derived from androgen-dependent human LNCaP and PC-3 is an androgen-independent cancer cell type. We demonstrated that <bold>1</bold> decreased the mRNA expression level of AR in C4-2 cells while <bold>1</bold> did not affect the mRNA expression level of AR in 22RV1. Therefore, the effect of <bold>1</bold> might not be dependent on AR, <bold>1</bold> might suppress proliferation and metastasis in PCa by disrupting other key cancer signaling pathways like mTOR/AKT and STAT3.</p></sec><sec sec-type="conclusion"><title>Conclusion</title><p>Overall, this study shows that an investigation of bioactive secondary metabolites from marine <italic toggle="yes">Vibrio</italic> species, strain DJA11 which led to the isolation of compound <bold>1</bold>. Compound <bold>1</bold> significantly suppressed cell viability, invasion, and cell growth. In addition, the protein levels of p-AKT, p-mTOR, p-STAT3, HSP90, and HSP70 were decreased in treatment with compound <bold>1</bold> in three PCa cells. Further studies are needed to identify adjuvant therapy strategies, such as mTOR inhibitors (<italic toggle="yes">e.g.</italic>, rapamycin) or AKT inhibitors, to enhance therapeutic efficacy in PCa therapy.</p></sec><sec sec-type="supplementary-material"><title>Supplemental Materials</title><p>Supplementary data for this paper are available on-line only at <ext-link xlink:href="http://jmb.or.kr" ext-link-type="uri">http://jmb.or.kr</ext-link>.</p><supplementary-material id="S1" position="float" content-type="local-data"><media xlink:href="jmb-35-e2502035-supple.pdf" id="d67e895" position="anchor"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>This research was supported by Institutional Core Project (2025M00500) of National Marine Biodiversity Institute of Korea (MABIK) and the Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (No. 2020R1A6C101B194).</p></ack><fn-group><fn fn-type="con"><p>
<bold>Author Contributions</bold>
</p><p>Conceptualization, S.P., and E.-Y., methodology, S.P., E.-Y.; validation, S.P., E.-Y., G.C, Y.H.J, H.K., and S.-J.N.; investigation, S.P., G.C, and E.-Y.; writing&#x02014;original draft preparation, S.P., E.-Y., H.K., and S.-J.; writing&#x02014;review and editing, S.P., E.-Y., H.K., and S.-J.N; supervision, Y.H.J, H.K., and S.-J.N.; All authors have read and agreed to the published version of the manuscript.</p></fn><fn fn-type="supported-by"><p>
<bold>Funding</bold>
</p><p>This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT; No. NRF-2022R1A2C1011848, RS-2024-00413760), an in-house grant from the National Marine Biodiversity Institute of Korea for &#x0201c;The development of useful materials derived from marine microorganisms and microalgae (2024), and the Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (No. 2020R1A6C101B194).</p></fn><fn><p>
<bold>Data Availability</bold>
</p><p>All data generated or analyzed during this study are included in this published article.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflict of Interest</bold>
</p><p>The authors declare no conflict of interest.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carroll</surname><given-names>AR</given-names></name>
<name><surname>Copp</surname><given-names>BR</given-names></name>
<name><surname>Davis</surname><given-names>RA</given-names></name>
<name><surname>Keyzers</surname><given-names>RA</given-names></name>
<name><surname>Prinsep</surname><given-names>MR</given-names></name>
</person-group><year>2021</year><article-title>Marine natural products</article-title><source>Nat. Prod. Rep.</source><volume>38</volume><fpage>362</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1039/D0NP00089B</pub-id><pub-id pub-id-type="pmid">33570537</pub-id>
</element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karthikeyan</surname><given-names>A</given-names></name>
<name><surname>Joseph</surname><given-names>A</given-names></name>
<name><surname>Nair</surname><given-names>BG</given-names></name>
</person-group><year>2022</year><article-title>Promising bioactive compounds from the marine environment and their potential effects on various diseases</article-title><source>J. Genet. Eng. Biotechnol.</source><volume>20</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.1186/s43141-021-00290-4</pub-id><pub-id pub-id-type="pmid">35080679</pub-id>
</element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Velmurugan</surname><given-names>P</given-names></name>
<name><surname>Venil</surname><given-names>CK</given-names></name>
<name><surname>Veera Ravi</surname><given-names>A</given-names></name>
<name><surname>Dufoss&#x000e9;</surname><given-names>L</given-names></name>
</person-group><year>2020</year><article-title>Marine bacteria is the cell factory to produce bioactive pigments: a prospective pigment source in the ocean</article-title><source>Front. Sustain. Food Syst.</source><volume>4</volume><elocation-id>589655</elocation-id><pub-id pub-id-type="doi">10.3389/fsufs.2020.589655</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Senadheera</surname><given-names>TR</given-names></name>
<name><surname>Hossain</surname><given-names>A</given-names></name>
<name><surname>Shahidi</surname><given-names>F</given-names></name>
</person-group><year>2023</year><article-title>Marine bioactives and their application in the food industry: a review</article-title><source>Appl. Sci.</source><volume>13</volume><elocation-id>12088</elocation-id><pub-id pub-id-type="doi">10.3390/app132112088</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baker-Austin</surname><given-names>C</given-names></name>
<name><surname>Trinanes</surname><given-names>JA</given-names></name>
<name><surname>Taylor</surname><given-names>NG</given-names></name>
<name><surname>Hartnell</surname><given-names>R</given-names></name>
<name><surname>Siitonen</surname><given-names>A</given-names></name>
<name><surname>Martinez-Urtaza</surname><given-names>J</given-names></name>
</person-group><year>2013</year><article-title>Emerging <italic toggle="yes">Vibrio</italic> risk at high latitudes in response to ocean warming</article-title><source>Nat. Clim. Change</source><volume>3</volume><fpage>73</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1038/nclimate1628</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makarieva</surname><given-names>T</given-names></name>
<name><surname>Shubina</surname><given-names>L</given-names></name>
<name><surname>Kurilenko</surname><given-names>V</given-names></name>
<name><surname>Isaeva</surname><given-names>M</given-names></name>
<name><surname>Chernysheva</surname><given-names>N</given-names></name>
<name><surname>Popov</surname><given-names>R</given-names></name>
<etal/>
</person-group><year>2019</year><article-title>Marine bacterium <italic toggle="yes">Vibrio</italic> sp. CB1-14 produces guanidine alkaloid 6-epi-monanchorin, previously isolated from marine polychaete and sponges</article-title><source>Mar. Drugs</source><volume>17</volume><fpage>213</fpage><pub-id pub-id-type="doi">10.3390/md17040213</pub-id><!--<pub-id pub-id-type="pmcid">PMC6521263</pub-id>--><pub-id pub-id-type="pmid">30987405</pub-id>
</element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Lin</surname><given-names>M</given-names></name>
<name><surname>Qin</surname><given-names>Y</given-names></name>
<name><surname>Lu</surname><given-names>H</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Gao</surname><given-names>C</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Anti-<italic toggle="yes">Vibrio</italic> potential of natural products from marine microorganisms</article-title><source>Eur. J. Med. Chem.</source><volume>252</volume><elocation-id>115330</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115330</pub-id><pub-id pub-id-type="pmid">37011553</pub-id>
</element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Agrawal</surname><given-names>S</given-names></name>
<name><surname>Adholeya</surname><given-names>A</given-names></name>
<name><surname>Deshmukh</surname><given-names>SK</given-names></name>
</person-group><year>2016</year><article-title>The pharmacological potential of non-ribosomal peptides from marine sponge and tunicates</article-title><source>Front. Pharmacol.</source><volume>7</volume><fpage>333</fpage><pub-id pub-id-type="doi">10.3389/fphar.2016.00333</pub-id><!--<pub-id pub-id-type="pmcid">PMC5078478</pub-id>--><pub-id pub-id-type="pmid">27826240</pub-id>
</element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wietz</surname><given-names>M</given-names></name>
<name><surname>Mansson</surname><given-names>M</given-names></name>
<name><surname>Gotfredsen</surname><given-names>CH</given-names></name>
<name><surname>Larsen</surname><given-names>TO</given-names></name>
<name><surname>Gram</surname><given-names>L</given-names></name>
</person-group><year>2010</year><article-title>Antibacterial compounds from marine <italic toggle="yes">Vibrionaceae</italic> isolated on a global expedition</article-title><source>Mar. Drugs</source><volume>8</volume><fpage>2946</fpage><lpage>2960</lpage><pub-id pub-id-type="doi">10.3390/md8122946</pub-id><!--<pub-id pub-id-type="pmcid">PMC3039463</pub-id>--><pub-id pub-id-type="pmid">21339958</pub-id>
</element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kitiyodom</surname><given-names>S</given-names></name>
<name><surname>Khemtong</surname><given-names>S</given-names></name>
<name><surname>Wongtavatchai</surname><given-names>J</given-names></name>
<name><surname>Chuanchuen</surname><given-names>R</given-names></name>
</person-group><year>2010</year><article-title>Characterization of antibiotic resistance in <italic toggle="yes">Vibrio</italic> spp. isolated from farmed marine shrimps (<italic toggle="yes">Penaeus monodon</italic>)</article-title><source>FEMS Microbiol. Ecol.</source><volume>72</volume><fpage>219</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6941.2010.00846.x</pub-id><pub-id pub-id-type="pmid">20236324</pub-id>
</element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bergengren</surname><given-names>O</given-names></name>
<name><surname>Pekala</surname><given-names>KR</given-names></name>
<name><surname>Matsoukas</surname><given-names>K</given-names></name>
<name><surname>Fainberg</surname><given-names>J</given-names></name>
<name><surname>Mungovan</surname><given-names>SF</given-names></name>
<name><surname>Bratt</surname><given-names>O</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>2022 update on prostate cancer epidemiology and risk factors-a systematic review</article-title><source>Eur. Urol.</source><volume>84</volume><fpage>191</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2023.04.021</pub-id><!--<pub-id pub-id-type="pmcid">PMC10851915</pub-id>--><pub-id pub-id-type="pmid">37202314</pub-id>
</element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><collab collab-type="author">Cancer IAfRo</collab><year>2024</year><article-title>Global cancer burden growing, amidst mounting need for services</article-title><source>Saudi Med. J.</source><volume>45</volume><fpage>326</fpage><lpage>327</lpage><pub-id pub-id-type="pmid">38438207</pub-id>
</element-citation></ref><ref id="ref13"><label>13</label><mixed-citation publication-type="other">Wild CP, Weiderpass E, Stewart BW. 2020. World cancer report.</mixed-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>TT</given-names></name>
<name><surname>Sikes</surname><given-names>RA</given-names></name>
<name><surname>Cui</surname><given-names>Q</given-names></name>
<name><surname>Thalmann</surname><given-names>GN</given-names></name>
<name><surname>Kao</surname><given-names>C</given-names></name>
<name><surname>Murphy</surname><given-names>CF</given-names></name>
<etal/>
</person-group><year>1998</year><article-title>Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate&#x02010;specific antigen&#x02010;producing tumors in athymic and SCID/bg mice using LNCaP and lineage&#x02010;derived metastatic sublines</article-title><source>Int. J. Cancer</source><volume>77</volume><fpage>887</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19980911)77:6&#x0003c;887::AID-IJC15&#x0003e;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">9714059</pub-id>
</element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Attardi</surname><given-names>BJ</given-names></name>
<name><surname>Burgenson</surname><given-names>J</given-names></name>
<name><surname>Hild</surname><given-names>SA</given-names></name>
<name><surname>Reel</surname><given-names>JR</given-names></name>
</person-group><year>2004</year><article-title>Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells</article-title><source>Mol. Cell. Endocrinol.</source><volume>222</volume><fpage>121</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2004.04.013</pub-id><pub-id pub-id-type="pmid">15249132</pub-id>
</element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tai</surname><given-names>S</given-names></name>
<name><surname>Sun</surname><given-names>Y</given-names></name>
<name><surname>Squires</surname><given-names>JM</given-names></name>
<name><surname>Zhang</surname><given-names>H</given-names></name>
<name><surname>Oh</surname><given-names>WK</given-names></name>
<name><surname>Liang</surname><given-names>CZ</given-names></name>
<etal/>
</person-group><year>2011</year><article-title>PC3 is a cell line characteristic of prostatic small cell carcinoma</article-title><source>Prostate</source><volume>71</volume><fpage>1668</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1002/pros.21383</pub-id><pub-id pub-id-type="pmid">21432867</pub-id>
</element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tortorella</surname><given-names>E</given-names></name>
<name><surname>Giantulli</surname><given-names>S</given-names></name>
<name><surname>Sciarra</surname><given-names>A</given-names></name>
<name><surname>Silvestri</surname><given-names>I</given-names></name>
</person-group><year>2023</year><article-title>AR and PI3K/AKT in prostate cancer: a tale of two interconnected pathways</article-title><source>Int. J. Mol. Sci.</source><volume>24</volume><fpage>2046</fpage><pub-id pub-id-type="doi">10.3390/ijms24032046</pub-id><!--<pub-id pub-id-type="pmcid">PMC9917224</pub-id>--><pub-id pub-id-type="pmid">36768370</pub-id>
</element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pungsrinont</surname><given-names>T</given-names></name>
<name><surname>Kallenbach</surname><given-names>J</given-names></name>
<name><surname>Baniahmad</surname><given-names>A</given-names></name>
</person-group><year>2021</year><article-title>Role of PI3K-AKT-mTOR pathway as a pro-survival signaling and resistancemediating mechanism to therapy of prostate cancer</article-title><source>Int. J. Mol. Sci.</source><volume>22</volume><elocation-id>11088</elocation-id><pub-id pub-id-type="doi">10.3390/ijms222011088</pub-id><!--<pub-id pub-id-type="pmcid">PMC8538152</pub-id>--><pub-id pub-id-type="pmid">34681745</pub-id>
</element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>HO</given-names></name>
<name><surname>Hong</surname><given-names>SE</given-names></name>
<name><surname>Kim</surname><given-names>JY</given-names></name>
<name><surname>Kim</surname><given-names>MR</given-names></name>
<name><surname>Chang</surname><given-names>YH</given-names></name>
<name><surname>Hong</surname><given-names>YJ</given-names></name>
<etal/>
</person-group><year>2019</year><article-title>Induction of HSP27 and HSP70 by constitutive overexpression of Redd1 confers resistance of lung cancer cells to ionizing radiation</article-title><source>Oncol. Rep.</source><volume>41</volume><fpage>3119</fpage><lpage>3126</lpage><pub-id pub-id-type="doi">10.3892/or.2019.7036</pub-id><pub-id pub-id-type="pmid">30864724</pub-id>
</element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chatterjee</surname><given-names>M</given-names></name>
<name><surname>Andrulis</surname><given-names>M</given-names></name>
<name><surname>St&#x000fc;hmer</surname><given-names>T</given-names></name>
<name><surname>M&#x000fc;ller</surname><given-names>E</given-names></name>
<name><surname>Hofmann</surname><given-names>C</given-names></name>
<name><surname>Steinbrunn</surname><given-names>T</given-names></name>
<etal/>
</person-group><year>2013</year><article-title>The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma</article-title><source>Haematologica</source><volume>98</volume><fpage>1132</fpage><pub-id pub-id-type="doi">10.3324/haematol.2012.066175</pub-id><!--<pub-id pub-id-type="pmcid">PMC3696618</pub-id>--><pub-id pub-id-type="pmid">23065523</pub-id>
</element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wesolowski</surname><given-names>R</given-names></name>
<name><surname>Abdel-Rasoul</surname><given-names>M</given-names></name>
<name><surname>Lustberg</surname><given-names>M</given-names></name>
<name><surname>Paskell</surname><given-names>M</given-names></name>
<name><surname>Shapiro</surname><given-names>CL</given-names></name>
<name><surname>Macrae</surname><given-names>ER</given-names></name>
</person-group><year>2014</year><article-title>Treatment-related mortality with everolimus in cancer patients</article-title><source>Oncologist</source><volume>19</volume><fpage>661</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2013-0355</pub-id><!--<pub-id pub-id-type="pmcid">PMC4041666</pub-id>--><pub-id pub-id-type="pmid">24794158</pub-id>
</element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jego</surname><given-names>G</given-names></name>
<name><surname>Hermetet</surname><given-names>F</given-names></name>
<name><surname>Girodon</surname><given-names>F</given-names></name>
<name><surname>Garrido</surname><given-names>C</given-names></name>
</person-group><year>2019</year><article-title>Chaperoning STAT3/5 by heat shock proteins: interest of their targeting in cancer therapy</article-title><source>Cancers</source><volume>12</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.3390/cancers12010021</pub-id><!--<pub-id pub-id-type="pmcid">PMC7017265</pub-id>--><pub-id pub-id-type="pmid">31861612</pub-id>
</element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crona</surname><given-names>DJ</given-names></name>
<name><surname>Whang</surname><given-names>YE</given-names></name>
</person-group><year>2017</year><article-title>Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance</article-title><source>Cancers</source><volume>9</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.3390/cancers9060067</pub-id><!--<pub-id pub-id-type="pmcid">PMC5483886</pub-id>--><pub-id pub-id-type="pmid">28604629</pub-id>
</element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Feng</surname><given-names>K</given-names></name>
<name><surname>Liu</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>W</given-names></name>
<name><surname>Kong</surname><given-names>P</given-names></name>
<name><surname>Tao</surname><given-names>Z</given-names></name>
<name><surname>Liu</surname><given-names>W</given-names></name>
</person-group><year>2023</year><article-title>Emerging proteins involved in castration-resistant prostate cancer via the AR-dependent and AR-independent pathways</article-title><source>Int. J. Oncol.</source><volume>63</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.3892/ijo.2023.5575</pub-id><!--<pub-id pub-id-type="pmcid">PMC10609492</pub-id>--><pub-id pub-id-type="pmid">37732538</pub-id>
</element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thomas</surname><given-names>E</given-names></name>
<name><surname>Thankan</surname><given-names>RS</given-names></name>
<name><surname>Purushottamachar</surname><given-names>P</given-names></name>
<name><surname>Huang</surname><given-names>W</given-names></name>
<name><surname>Kane</surname><given-names>MA</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<etal/>
</person-group><year>2022</year><article-title>Novel AR/AR-V7 and Mnk1/2 degrader, VNPP433-3&#x003b2;: molecular mechanisms of action and efficacy in AR-overexpressing castration resistant prostate cancer in vitro and in vivo models</article-title><source>Cells</source><volume>11</volume><fpage>2699</fpage><pub-id pub-id-type="doi">10.3390/cells11172699</pub-id><!--<pub-id pub-id-type="pmcid">PMC9454942</pub-id>--><pub-id pub-id-type="pmid">36078112</pub-id>
</element-citation></ref><ref id="ref26"><label>26</label><mixed-citation publication-type="other">Morgans AK, Shore N, Cope D, McNatty A, Moslehi J, Gomella L, <italic toggle="yes">et al</italic>. 2021. Presented at the urologic oncology: seminars and Original Investigations.</mixed-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>SO</given-names></name>
<name><surname>Andey</surname><given-names>T</given-names></name>
<name><surname>Jin</surname><given-names>UH</given-names></name>
<name><surname>Kim</surname><given-names>K</given-names></name>
<name><surname>Sachdeva</surname><given-names>M</given-names></name>
<name><surname>Safe</surname><given-names>S</given-names></name>
</person-group><year>2012</year><article-title>The nuclear receptor TR3 regulates mTORC1 signaling in lung cancer cells expressing wild-type p53</article-title><source>Oncogene</source><volume>31</volume><fpage>3265</fpage><lpage>3276</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.504</pub-id><!--<pub-id pub-id-type="pmcid">PMC3299891</pub-id>--><pub-id pub-id-type="pmid">22081070</pub-id>
</element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hedrick</surname><given-names>E</given-names></name>
<name><surname>Lee</surname><given-names>SO</given-names></name>
<name><surname>Doddapaneni</surname><given-names>R</given-names></name>
<name><surname>Singh</surname><given-names>M</given-names></name>
<name><surname>Safe</surname><given-names>S</given-names></name>
</person-group><year>2016</year><article-title>NR4A1 antagonists inhibit &#x003b2;1-integrin-dependent breast cancer cell migration</article-title><source>Mol. Cell. Biol.</source><volume>36</volume><fpage>1383</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1128/MCB.00912-15</pub-id><!--<pub-id pub-id-type="pmcid">PMC4836213</pub-id>--><pub-id pub-id-type="pmid">26929200</pub-id>
</element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gamage</surname><given-names>CD</given-names></name>
<name><surname>Kim</surname><given-names>JH</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Ta&#x0015f;</surname><given-names>&#x00130;</given-names></name>
<name><surname>Park</surname><given-names>SY</given-names></name>
<name><surname>Zhou</surname><given-names>R</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Libertellenone T, a novel compound isolated from endolichenic fungus, induces G2/M phase arrest, apoptosis, and autophagy by activating the ROS/JNK pathway in colorectal cancer cells</article-title><source>Cancers</source><volume>15</volume><fpage>489</fpage><pub-id pub-id-type="doi">10.3390/cancers15020489</pub-id><pub-id pub-id-type="pmid">36672439</pub-id>
</element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulat</surname><given-names>S</given-names></name>
<name><surname>Yang</surname><given-names>I</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Hwang</surname><given-names>S</given-names></name>
<name><surname>Zhou</surname><given-names>R</given-names></name>
<name><surname>Gamage</surname><given-names>CD</given-names></name>
<etal/>
</person-group><year>2024</year><article-title>Anithiactin D, a phenylthiazole natural product from Mudflatderived <italic toggle="yes">Streptomyces</italic> sp., suppresses motility of cancer cells</article-title><source>Mar. Drugs</source><volume>22</volume><fpage>88</fpage><pub-id pub-id-type="doi">10.3390/md22020088</pub-id><pub-id pub-id-type="pmid">38393059</pub-id>
</element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulat</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>W</given-names></name>
<name><surname>Hwang</surname><given-names>JH</given-names></name>
<name><surname>Zhou</surname><given-names>R</given-names></name>
<name><surname>Gamage</surname><given-names>CD</given-names></name>
<name><surname>Varl&#x00131;</surname><given-names>M</given-names></name>
<etal/>
</person-group><year>2025</year><article-title>Atraric acid induces hair growth through the stimulation of sonic Hedgehog/GLI1 in human dermal papilla cells</article-title><source>Stem Cell Rev. Rep.</source><volume>21</volume><fpage>283</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1007/s12015-024-10798-0</pub-id><pub-id pub-id-type="pmid">39361105</pub-id>
</element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>R</given-names></name>
<name><surname>Liu</surname><given-names>R</given-names></name>
<name><surname>Kang</surname><given-names>KB</given-names></name>
<name><surname>Kim</surname><given-names>W</given-names></name>
<name><surname>Hur</surname><given-names>JS</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
</person-group><year>2024</year><article-title>The depside derivative pericodepside inhibits cancer cell metastasis and proliferation by suppressing epithelial-mesenchymal transition</article-title><source>ACS Omega</source><volume>9</volume><fpage>6828</fpage><lpage>6836</lpage><pub-id pub-id-type="doi">10.1021/acsomega.3c08136</pub-id><!--<pub-id pub-id-type="pmcid">PMC10870356</pub-id>--><pub-id pub-id-type="pmid">38371795</pub-id>
</element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulat</surname><given-names>S</given-names></name>
<name><surname>Hillman</surname><given-names>PF</given-names></name>
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Asolkar</surname><given-names>RN</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Zhou</surname><given-names>R</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Marinobazzanan, a bazzanane-type sesquiterpenoid, suppresses the cell motility and tumorigenesis in cancer cells</article-title><source>Mar. Drugs</source><volume>21</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.3390/md21030153</pub-id><pub-id pub-id-type="pmid">36976200</pub-id>
</element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Varl&#x00131;</surname><given-names>M</given-names></name>
<name><surname>Lee</surname><given-names>EY</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Zhou</surname><given-names>R</given-names></name>
<name><surname>Ta&#x0015f;</surname><given-names>&#x00130;</given-names></name>
<name><surname>Pulat</surname><given-names>S</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>1'-<italic toggle="yes">O</italic>-methyl-averantin isolated from the endolichenic fungus <italic toggle="yes">Jackrogersella</italic> sp. EL001672 suppresses colorectal cancer stemness via sonic Hedgehog and Notch signaling</article-title><source>Sci. Rep.</source><volume>13</volume><fpage>2811</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-28773-z</pub-id><!--<pub-id pub-id-type="pmcid">PMC9935543</pub-id>--><pub-id pub-id-type="pmid">36797277</pub-id>
</element-citation></ref><ref id="ref35"><label>35</label><mixed-citation publication-type="other">Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, <italic toggle="yes">et al</italic>. 2015. Presented at the Seminars in cancer biology.</mixed-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Rong</surname><given-names>Z</given-names></name>
<name><surname>Shou</surname><given-names>C</given-names></name>
</person-group><year>2019</year><article-title>Mycoplasma hyorhinis infection promotes gastric cancer cell motility via &#x003b2;&#x02010;catenin signaling</article-title><source>Cancer Med.</source><volume>8</volume><fpage>5301</fpage><lpage>5312</lpage><pub-id pub-id-type="doi">10.1002/cam4.2357</pub-id><!--<pub-id pub-id-type="pmcid">PMC6718539</pub-id>--><pub-id pub-id-type="pmid">31321908</pub-id>
</element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>J</given-names></name>
<name><surname>Masri</surname><given-names>J</given-names></name>
<name><surname>Bernath</surname><given-names>A</given-names></name>
<name><surname>Nishimura</surname><given-names>RN</given-names></name>
<name><surname>Gera</surname><given-names>J</given-names></name>
</person-group><year>2008</year><article-title>Hsp70 associates with rictor and is required for mTORC2 formation and activity</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>372</volume><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.05.086</pub-id><pub-id pub-id-type="pmid">18505677</pub-id>
</element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Conciatori</surname><given-names>F</given-names></name>
<name><surname>Ciuffreda</surname><given-names>L</given-names></name>
<name><surname>Bazzichetto</surname><given-names>C</given-names></name>
<name><surname>Falcone</surname><given-names>I</given-names></name>
<name><surname>Pilotto</surname><given-names>S</given-names></name>
<name><surname>Bria</surname><given-names>E</given-names></name>
<etal/>
</person-group><year>2018</year><article-title>mTOR cross-talk in cancer and potential for combination therapy</article-title><source>Cancers</source><volume>10</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.3390/cancers10010023</pub-id><!--<pub-id pub-id-type="pmcid">PMC5789373</pub-id>--><pub-id pub-id-type="pmid">29351204</pub-id>
</element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulat</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>DA</given-names></name>
<name><surname>Hillman</surname><given-names>PF</given-names></name>
<name><surname>Oh</surname><given-names>DC</given-names></name>
<name><surname>Kim</surname><given-names>H</given-names></name>
<name><surname>Nam</surname><given-names>SJ</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>Actinoquinazolinone, a new quinazolinone derivative from a marine <italic toggle="yes">Bacterium Streptomyces</italic> sp. CNQ-617, suppresses the motility of gastric cancer cells</article-title><source>Mar. Drugs</source><volume>21</volume><fpage>489</fpage><pub-id pub-id-type="doi">10.3390/md21090489</pub-id><!--<pub-id pub-id-type="pmcid">PMC10532864</pub-id>--><pub-id pub-id-type="pmid">37755102</pub-id>
</element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bito</surname><given-names>T</given-names></name>
<name><surname>Sumita</surname><given-names>N</given-names></name>
<name><surname>Ashida</surname><given-names>M</given-names></name>
<name><surname>Budiyanto</surname><given-names>A</given-names></name>
<name><surname>Ueda</surname><given-names>M</given-names></name>
<name><surname>Ichihashi</surname><given-names>M</given-names></name>
<etal/>
</person-group><year>2011</year><article-title>Inhibition of epidermal growth factor receptor and PI3K/Akt signaling suppresses cell proliferation and survival through regulation of Stat3 activation in human cutaneous squamous cell carcinoma</article-title><source>J. Skin Cancer</source><volume>2011</volume><elocation-id>874571</elocation-id><pub-id pub-id-type="doi">10.1155/2011/874571</pub-id><!--<pub-id pub-id-type="pmcid">PMC3005828</pub-id>--><pub-id pub-id-type="pmid">21197106</pub-id>
</element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Longo</surname><given-names>JF</given-names></name>
<name><surname>Brosius</surname><given-names>SN</given-names></name>
<name><surname>Black</surname><given-names>L</given-names></name>
<name><surname>Worley</surname><given-names>SH</given-names></name>
<name><surname>Wilson</surname><given-names>RC</given-names></name>
<name><surname>Roth</surname><given-names>KA</given-names></name>
<etal/>
</person-group><year>2019</year><article-title>ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms</article-title><source>Cell Commun. Signal.</source><volume>17</volume><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/s12964-019-0388-5</pub-id><!--<pub-id pub-id-type="pmcid">PMC6621970</pub-id>--><pub-id pub-id-type="pmid">31291965</pub-id>
</element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shorning</surname><given-names>BY</given-names></name>
<name><surname>Dass</surname><given-names>MS</given-names></name>
<name><surname>Smalley</surname><given-names>MJ</given-names></name>
<name><surname>Pearson</surname><given-names>HB</given-names></name>
</person-group><year>2020</year><article-title>The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling</article-title><source>Int. J. Mol. Sci.</source><volume>21</volume><fpage>4507</fpage><pub-id pub-id-type="doi">10.3390/ijms21124507</pub-id><!--<pub-id pub-id-type="pmcid">PMC7350257</pub-id>--><pub-id pub-id-type="pmid">32630372</pub-id>
</element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fujita</surname><given-names>K</given-names></name>
<name><surname>Nonomura</surname><given-names>N</given-names></name>
</person-group><year>2019</year><article-title>Role of androgen receptor in prostate cancer: a review</article-title><source>World J. Men's Health</source><volume>37</volume><fpage>288</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.5534/wjmh.180040</pub-id><!--<pub-id pub-id-type="pmcid">PMC6704300</pub-id>--><pub-id pub-id-type="pmid">30209899</pub-id>
</element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hynes</surname><given-names>NE</given-names></name>
<name><surname>MacDonald</surname><given-names>G</given-names></name>
</person-group><year>2009</year><article-title>ErbB receptors and signaling pathways in cancer</article-title><source>Curr. Opin. Cell Biol.</source><volume>21</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2008.12.010</pub-id><pub-id pub-id-type="pmid">19208461</pub-id>
</element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brooks</surname><given-names>AJ</given-names></name>
<name><surname>Putoczki</surname><given-names>T</given-names></name>
</person-group><year>2020</year><article-title>JAK-STAT signalling pathway in cancer</article-title><source>Cancers</source><volume>12</volume><fpage>1971</fpage><pub-id pub-id-type="doi">10.3390/cancers12071971</pub-id><!--<pub-id pub-id-type="pmcid">PMC7409105</pub-id>--><pub-id pub-id-type="pmid">32698360</pub-id>
</element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pham</surname><given-names>VC</given-names></name>
<name><surname>Nguyen</surname><given-names>TKC</given-names></name>
<name><surname>Vu</surname><given-names>TQ</given-names></name>
<name><surname>Pham</surname><given-names>TB</given-names></name>
<name><surname>Phan</surname><given-names>VK</given-names></name>
<name><surname>Nguyen</surname><given-names>HN</given-names></name>
<etal/>
</person-group><year>2014</year><article-title>Antimicrobial constituents from the bacillus megaterium lc isolated from marine sponge <italic toggle="yes">Haliclona oculata</italic></article-title><source>Nat. Prod. Sci.</source><volume>20</volume><fpage>202</fpage><lpage>205</lpage></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chintharlapalli</surname><given-names>S</given-names></name>
<name><surname>Burghardt</surname><given-names>R</given-names></name>
<name><surname>Papineni</surname><given-names>S</given-names></name>
<name><surname>Ramaiah</surname><given-names>S</given-names></name>
<name><surname>Yoon</surname><given-names>K</given-names></name>
<name><surname>Safe</surname><given-names>S</given-names></name>
</person-group><year>2005</year><article-title>Activation of Nur77 by selected 1, 1-Bis (3'-indolyl)-1-(p-substituted phenyl) methanes induces apoptosis through nuclear pathways</article-title><source>J. Biol. Chem.</source><volume>280</volume><fpage>24903</fpage><lpage>24914</lpage><pub-id pub-id-type="doi">10.1074/jbc.M500107200</pub-id><pub-id pub-id-type="pmid">15871945</pub-id>
</element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>SO</given-names></name>
<name><surname>Jin</surname><given-names>UH</given-names></name>
<name><surname>Kang</surname><given-names>JH</given-names></name>
<name><surname>Kim</surname><given-names>SB</given-names></name>
<name><surname>Guthrie</surname><given-names>AS</given-names></name>
<name><surname>Sreevalsan</surname><given-names>S</given-names></name>
<etal/>
</person-group><year>2014</year><article-title>The orphan nuclear receptor NR4A1 (Nur77) regulates oxidative and endoplasmic reticulum stress in pancreatic cancer cells</article-title><source>Mol. Cancer Res.</source><volume>12</volume><fpage>527</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0567</pub-id><!--<pub-id pub-id-type="pmcid">PMC4407472</pub-id>--><pub-id pub-id-type="pmid">24515801</pub-id>
</element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shrestha</surname><given-names>R</given-names></name>
<name><surname>Mohankumar</surname><given-names>K</given-names></name>
<name><surname>Jin</surname><given-names>UH</given-names></name>
<name><surname>Martin</surname><given-names>G</given-names></name>
<name><surname>Safe</surname><given-names>S</given-names></name>
</person-group><year>2021</year><article-title>The histone methyltransferase gene G9A is regulated by nuclear receptor 4A1 in alveolar rhabdomyosarcoma cells</article-title><source>Mol. Cancer Ther.</source><volume>20</volume><fpage>612</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-20-0474</pub-id><!--<pub-id pub-id-type="pmcid">PMC7933077</pub-id>--><pub-id pub-id-type="pmid">33277444</pub-id>
</element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>TH</given-names></name>
<name><surname>Park</surname><given-names>JM</given-names></name>
<name><surname>Kim</surname><given-names>MY</given-names></name>
<name><surname>Ahn</surname><given-names>YH</given-names></name>
</person-group><year>2017</year><article-title>The role of CREB3L4 in the proliferation of prostate cancer cells</article-title><source>Sci. Rep.</source><volume>7</volume><elocation-id>45300</elocation-id><pub-id pub-id-type="doi">10.1038/srep45300</pub-id><!--<pub-id pub-id-type="pmcid">PMC5364418</pub-id>--><pub-id pub-id-type="pmid">28338058</pub-id>
</element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Drudge-Coates</surname><given-names>L</given-names></name>
<name><surname>Oh</surname><given-names>WK</given-names></name>
<name><surname>Tombal</surname><given-names>B</given-names></name>
<name><surname>Delacruz</surname><given-names>A</given-names></name>
<name><surname>Tomlinson</surname><given-names>B</given-names></name>
<name><surname>Ripley</surname><given-names>AV</given-names></name>
<etal/>
</person-group><year>2018</year><article-title>Recognizing symptom burden in advanced prostate cancer: a global patient and caregiver survey</article-title><source>Clin. Genitourin. Cancer</source><volume>16</volume><fpage>e411</fpage><lpage>e419</lpage><pub-id pub-id-type="doi">10.1016/j.clgc.2017.09.015</pub-id><pub-id pub-id-type="pmid">29111175</pub-id>
</element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sadrkhanloo</surname><given-names>M</given-names></name>
<name><surname>Paskeh</surname><given-names>MDA</given-names></name>
<name><surname>Hashemi</surname><given-names>M</given-names></name>
<name><surname>Raesi</surname><given-names>R</given-names></name>
<name><surname>Motahhary</surname><given-names>M</given-names></name>
<name><surname>Saghari</surname><given-names>S</given-names></name>
<etal/>
</person-group><year>2023</year><article-title>STAT3 signaling in prostate cancer progression and therapy resistance: an oncogenic pathway with diverse functions</article-title><source>Biomed. Pharmacother.</source><volume>158</volume><elocation-id>114168</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.114168</pub-id><pub-id pub-id-type="pmid">36916439</pub-id>
</element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>X</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Yan</surname><given-names>X</given-names></name>
<name><surname>DiSanto</surname><given-names>ME</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
</person-group><year>2022</year><article-title>Heat shock protein 70 and 90 family in prostate cancer</article-title><source>Life</source><volume>12</volume><fpage>1489</fpage><pub-id pub-id-type="doi">10.3390/life12101489</pub-id><!--<pub-id pub-id-type="pmcid">PMC9605364</pub-id>--><pub-id pub-id-type="pmid">36294924</pub-id>
</element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehralivand</surname><given-names>S</given-names></name>
<name><surname>Thomas</surname><given-names>C</given-names></name>
<name><surname>Puhr</surname><given-names>M</given-names></name>
<name><surname>Claessens</surname><given-names>F</given-names></name>
<name><surname>van de Merbel</surname><given-names>AF</given-names></name>
<name><surname>Dubrovska</surname><given-names>A</given-names></name>
<etal/>
</person-group><year>2024</year><article-title>New advances of the androgen receptor in prostate cancer: report from the 1st International Androgen Receptor Symposium</article-title><source>J. Transl. Med.</source><volume>22</volume><fpage>71</fpage><pub-id pub-id-type="doi">10.1186/s12967-024-04878-5</pub-id><pub-id pub-id-type="pmid">38238739</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Fig. 1</label><caption><title>Chemical structure of 1 (7,7-bis(3-indolyl)-<italic toggle="yes">p</italic>-cresol).</title></caption><graphic xlink:href="jmb-35-e2502035-f1" position="float"/></fig><fig position="float" id="F2"><label>Fig. 2</label><caption><title>The effect of 1 on the cell viability of PCa cell lines.</title><p>(<bold>A</bold>) Relative cell viability of 22Rv1, C4-2, PC-3, and HEK293T were measured by MTT after treatment of 10, 25, 50, and 100 &#x003bc;M of 1. (<bold>B</bold>) IC<sub>50</sub> values of 1 against the 22Rv1, C4-2, PC-3, and HEK293T. Data are presented as mean &#x000b1; SD, <italic toggle="yes">n</italic> = 3. ***<italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="jmb-35-e2502035-f2" position="float"/></fig><fig position="float" id="F3"><label>Fig. 3</label><caption><title>The effects of 1 on the motility and proliferation of PCa cell lines.</title><p>(<bold>A</bold>) Representative images of each insertion in the clonogenic assay. (<bold>B</bold>) The relative percentage of colony numbers on 22Rv1, C4-2, and PC-3 cells. (<bold>C</bold>) Representative images of each insertion in the invasion assay. (<bold>D</bold>) Relative percentage of invaded 22Rv1, C4-2, and PC-3 cells. Data are presented as mean &#x000b1; SD, *<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01; ***<italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="jmb-35-e2502035-f3" position="float"/></fig><fig position="float" id="F4"><label>Fig. 4</label><caption><title>Three-dimensional and two-dimensional structural interactions of important target receptors with 1, pink indicating the donor and green indicating the acceptor.</title><p>(<bold>A</bold>) Interaction of mTOR with <bold>1</bold> and interaction of HSP90 with <bold>1</bold>. (<bold>B</bold>) Western blot analysis of HSP90, HSP70, p-AKT, p- mTOR, and p-STAT3. (<bold>C</bold>) Relative protein levels of HSP90, HSP70, p-AKT, p-mTOR, and p-STAT3. Data are presented as mean &#x000b1; SD, <italic toggle="yes">n</italic> = 3. *<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01; ***<italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="jmb-35-e2502035-f4" position="float"/></fig><fig position="float" id="F5"><label>Fig. 5</label><caption><title>Effect of 1 on the mRNA expression of ErbB4, PDK1, STAT3, HSP70, and HSP90.</title><p>(<bold>A</bold>) Relative mRNA levels of of ErbB4, PDK1, STAT3, HSP70, and HSP90 in 22RV1. (<bold>B</bold>) Relative mRNA levels of ErbB4, PDK1, STAT3, HSP70, and HSP90 in C4-2. (<bold>C</bold>) The mRNA expression levels of ErbB4, PDK1, STAT3, HSP70, and HSP90 in PC-3. Data are presented as mean &#x000b1; SD, <italic toggle="yes">n</italic> = 3. *<italic toggle="yes">p</italic> &#x0003c; 0.05; **<italic toggle="yes">p</italic> &#x0003c; 0.01; ***<italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="jmb-35-e2502035-f5" position="float"/></fig><fig position="float" id="F6"><label>Fig. 6</label><caption><title>The effect of 1 on AR.</title><p>(<bold>A</bold>) Interaction of AR with 1. (<bold>B</bold>) Interaction of AR with testosterone. (<bold>C</bold>) Effect of 1 on mRNA expression level of AR in 22Rv1, and C4-2 cells. Data are presented as mean &#x000b1; SD, <italic toggle="yes">n</italic> = 3. ***<italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="jmb-35-e2502035-f6" position="float"/></fig><fig position="float" id="F7"><label>Fig. 7</label><caption><title>(<bold>A</bold>) Genes in common between PCa and 1 using the Venny.</title><p>This figure compares the total number of target genes of <bold>1</bold> and PCa and shows the overlap between them at the intersection. (<bold>B</bold>) Gene network analysis by STRING. (<bold>C</bold>) Pathway assessment chart of the genes using the Shinny. Pathways are color-coded according to FDR.</p></caption><graphic xlink:href="jmb-35-e2502035-f7" position="float"/></fig></floats-group></article>